Clinical Trial

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

Name: Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC — clinical trial record (NCT07765836)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EKLAVYA-HRD

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).

Trial Details

NCT Number	NCT07765836
Lead Sponsor	Massachusetts General Hospital Collaborators: Xilio Development, Inc., Incyte Corporation, Lustgarten Foundation
Conditions	Pancreatic Cancer Metastatic
Enrollment	40 participants
Start Date	2027-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-14